Medivir AB, a pharmaceutical company based in Sweden, focuses on developing innovative drugs to address unmet medical needs in cancer treatment. Their ESG score stands at 27.6, categorizing them as a medium-risk investment. With a focus on sustainability and governance, Medivir invests in areas where current treatment options are limited. Their flagship drug, MIV-818, targets liver tumors with minimal side effects. Additionally, they have out-licensed Birinapant, a SMAC mimetic, for the treatment of solid tumors in collaboration with IGM antibodies.